Eureka Therapeutics Announces Publication of Crystal Structure of TCR Mimic Redirected T Cells Targeting Alpha-Fetoprotein (AFP) for Liver Cancer

EMERYVILLE, Calif.--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced the publication of a study in Nature’s Scientific Reports entitled “Validation and promise of a TCR mimic antibody for cancer immunotherapy of hepatocellular carcinoma”. The study was led by Dr....

Click to view original post